Telomir details new Telomir-1 prostate cancer data

Telomir Pharmaceuticals, Inc. reported new preclinical findings for its lead investigational compound, Telomir-1, in aggressive prostate cancer models.

Rhea-AI Filing Summary

Telomir Pharmaceuticals, Inc. reported new preclinical findings for its lead investigational compound, Telomir-1, in aggressive prostate cancer models. The studies showed that Telomir-1 can reset abnormal DNA methylation and restore the function of two key tumor suppressor genes, MASPIN and RASSF1A, which are often silenced in cancer and are closely linked to metastasis and treatment resistance.

In an in vivo aggressive prostate cancer model, MASPIN was silenced by DNA hypermethylation, and Telomir-1 reversed chemotherapy-induced DNA methylation to restore MASPIN activity. Telomir-1 also reduced RASSF1A methylation in a dose-dependent manner, with stronger effects when combined with chemotherapy. The company states that reactivating these genes may help restore natural tumor defenses, counteract chemotherapy-induced resistance, and limit cancer metastasis as part of its ongoing preclinical and IND-enabling development of Telomir-1.

Insights

Biotech and drug development analyst

Telomir-1 shows promising preclinical epigenetic effects, but data remain early-stage.

The disclosure describes how Telomir-1 affected DNA methylation of two tumor suppressor genes, MASPIN and RASSF1A, in aggressive prostate cancer models. These genes are associated with blocking invasion, limiting metastasis, and improving chemotherapy responsiveness, and the results suggest Telomir-1 can reverse hypermethylation to restore their function in preclinical settings.

The findings include in vivo reversal of chemotherapy-induced DNA methylation for MASPIN and dose-dependent reduction of RASSF1A methylation, with stronger effects when Telomir-1 is combined with chemotherapy. The company characterizes this as expanding the potential to restore natural tumor defenses and counteract treatment resistance, while emphasizing that Telomir-1 remains in preclinical development with IND-enabling studies underway.

From an investment perspective, these results add mechanistic support around Telomir-1’s epigenetic action but do not yet provide human efficacy or safety data. Subsequent disclosures from the IND-enabling work and any future clinical trials will be needed to understand how these preclinical mechanisms translate into clinical outcomes.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Telomir Pharmaceuticals (TELO) announce about Telomir-1 in this 8-K?

The company announced new preclinical cancer results showing that its investigational compound Telomir-1 reset abnormal DNA methylation in aggressive prostate cancer models, restoring the function of two tumor suppressor genes, MASPIN and RASSF1A.

Why are MASPIN and RASSF1A important in Telomir Pharmaceuticals (TELO) research?

MASPIN and RASSF1A are tumor suppressor genes that help block invasion, limit metastasis, regulate cell cycle brakes and apoptosis, and enhance chemotherapy responsiveness. The filing states that both are frequently silenced in aggressive cancers by DNA hypermethylation, and Telomir-1 was shown to reverse or reduce this hypermethylation in preclinical models.

What specific preclinical effects did Telomir-1 show in prostate cancer models?

In an aggressive prostate cancer model in vivo, Telomir-1 reversed chemotherapy-induced DNA hypermethylation to restore MASPIN activity. It also reduced RASSF1A methylation in a dose-dependent manner, with stronger effects when Telomir-1 was combined with chemotherapy.

How does Telomir Pharmaceuticals describe the potential impact of Telomir-1 based on these findings?

The company states that by reactivating MASPIN and RASSF1A through DNA methylation reset, Telomir-1 expands the potential to restore natural tumor defenses, counteract chemotherapy-induced resistance, and help limit cancer metastasis in aggressive prostate cancer models.

What development stage is Telomir-1 currently in for Telomir Pharmaceuticals (TELO)?

Telomir-1 remains in the preclinical stage. The company reports that it is continuing preclinical development and is currently advancing the program with IND-enabling studies.

Does this Telomir Pharmaceuticals (TELO) update include clinical trial or financial results?

No. The update focuses on preclinical results in aggressive prostate cancer models and notes that Telomir-1 is in IND-enabling studies. It does not present clinical trial data or financial results.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/06/2025 - 04:01 PM Learn about SEC filing dates

false 0001971532 0001971532 2025-10-06 2025-10-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 6, 2025

TELOMIR PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in its Charter)

Florida		001-41952		87-2606031
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

100 SE 2nd St, Suite 2000, #1009

Miami, Florida
(Address of Principal Executive Offices)

Registrant’s telephone number, including area code: (786) 396-6723

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

	☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
	☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
	☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
	☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, no par value		TELO		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events

Telomir Pharmaceuticals Announces New Findings in a Prostate Cancer Model Demonstrating Telomir-1 Also Resets DNA Methylation of Tumor Suppressor Genes Implicated in Two of the Most Persistent Challenges in Oncology—Metastasis and Treatment Resistance

Findings show that Telomir-1 restores the body’s natural tumor suppressor defenses by reversing abnormal DNA methylation of MASPIN and RASSF1A — genes that help block invasion, limit metastasis, and improve chemotherapy responsiveness in aggressive prostate cancer models.

On October 6, 2025, Telomir Pharmaceuticals, Inc. (the “Company”) announced new cancer results from preclinical studies of its lead investigational compound, Telomir-1, in aggressive prostate cancer models.

The studies demonstrated that Telomir-1 resets abnormal DNA methylation to restore the function of two additional critical tumor suppressor genes — MASPIN and RASSF1A. Both genes are frequently silenced in cancer, a change that is closely linked to metastasis and treatment resistance, two of the most significant challenges in oncology.

● MASPIN (“tumor suppressor shield”):

MASPIN is a natural defense protein that blocks tumor invasion, regulates cell migration and angiogenesis, promotes apoptosis, and enhances treatment sensitivity. In an aggressive prostate-cancer model in vivo, MASPIN was silenced by DNA hypermethylation. Telomir-1 reversed the chemotherapy-induced DNA methylation to restore MASPIN activity, consistent with reactivation of this key tumor-suppressor pathway.

● RASSF1A (“guardian gene”, also called SERPINB5):

RASSF1A is a critical regulator of cell cycle brakes, apoptosis, and suppression of metastasis. It is commonly silenced in aggressive cancers by hypermethylation. Telomir-1 reduced RASSF1A methylation in a dose-dependent manner, with stronger effects when combined with chemotherapy.

● Implication: These results suggest Telomir-1 may reactivate natural tumor defenses, counteract chemotherapy-induced resistance mechanisms, and help limit metastasis — two of the most persistent challenges in oncology.

By reactivating MASPIN and RASSF1A through DNA methylation reset, Telomir-1 expands the potential to restore natural tumor defenses, counteract chemotherapy-induced resistance, and help limit cancer metastasis.

The Company is continuing its preclinical development of Telomir-1 and is currently advancing the program with IND-enabling studies.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	TELOMIR PHARMACEUTICALS, INC.
Dated: October 6, 2025	By:	/s/ Erez Aminov
	Name:	Erez Aminov
	Title:	Chief Executive Officer